Physician profile
David Hyun
NPI 1255312005
$6,313.48
in general payments reported to CMS, 2019-2025
20 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $391 · 2021: $473 · 2022: $1,040 · 2023: $1,568 · 2024: $1,079 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,213.17 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $1,125.34 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $838.38 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $555.41 | 2019-2025 | |
| Pfizer INC. | $536.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $487.10 | 2019-2024 | Farxiga, Brilinta |
| Boston Scientific Corporation | $355.22 | 2023-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $300.60 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.21 | 2023-2025 | Jardiance |
| Portola Pharmaceuticals, LLC | $124.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $123.67 | 2019-2024 | |
| Novo Nordisk INC | $73.83 | 2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $69.34 | 2019-2022 | |
| Esperion Therapeutics, INC. | $60.01 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $47.43 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $40.41 | 2023-2024 | Mitraclip, Jot Dx |
| Kowa Pharmaceuticals America, INC. | $36.33 | 2019-2021 | |
| Gilead Sciences, INC. | $28.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.73 | 2022 | |
| Glaxosmithkline, LLC. | $17.37 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hyun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.